secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001193125-23-050965
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte increases ATM equity offering capacity from $150M to $400M
------------------------------------------------------------------

- Amendment to Sales Agreement with Jefferies raises aggregate offering amount to $400M.
- As of Feb 27, 2023, ~$137.8M had been sold under the prior $150M ATM program.
- Material terms unchanged; sales made via at-the-market offerings on Nasdaq.
- Shares registered under existing shelf registration statement; no obligation to sell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523050965/0001193125-23-050965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523050965/d448993d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-050965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer